Helus Pharma Inc.

Helus Pharma Inc.

HELP - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$319.66M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Helus Pharma Inc.Helus Pharma Inc.0--70%--
$25.50

Target Price by Analysts

317.3% upsideHelus Pharma Target Price DetailsTarget Price
$4.98

Current Fair Value

18.4% downside

Overvalued by 18.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$319.66 Million
Enterprise Value$153.57 Million
Earnings per Share$-4.23
Beta0.54
Outstanding Shares52,318,151

Return

Return on Equity-70.01%ROE
Return on Assets-65.27%
Return on Invested Capital-68.27%

Valuation & Multiples

P/E Ratio-P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio1.53Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-0.93
Enterprise Value to Net Income-1
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 16, 2026
EPS
-$1.41
Est. -$0.67
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
February 12, 2027
EPS Estimate
-$0.68
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Cybin Inc

100 employees
CEO: Michael I. Halstead

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer fr...

Helus Pharma Insider Information FAQ

Stockcircle shows 1 open-market insider purchase for Helus Pharma in the last six months from SEC Form 4 reports by executives, directors, and other insiders.

Form 4 insider trades are added as new filings are imported. Top investor 13F holdings refresh after each quarterly filing cycle. Politician trade disclosures are added when new reports are published on Stockcircle.